|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/22/20 Accelerated Pharma, Inc. 10-Q 9/30/19 39:1.6M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 191K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 15K
23: R1 Document and Entity Information HTML 44K
36: R2 Condensed Consolidated Balance Sheets HTML 83K
29: R3 Condensed Consolidated Balance Sheets HTML 39K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Operations HTML 54K
and Comprehensive Loss (Unaudited)
24: R5 Condensed Consolidated Statements of Changes in HTML 60K
Stockholders' Deficiency (Unaudited)
37: R6 Condensed Consolidated Statements of Cash Flows HTML 72K
(Unaudited)
30: R7 Business HTML 21K
14: R8 Going Concern and Management's Liquidity Plans HTML 21K
26: R9 Significant Accounting Policies HTML 36K
19: R10 Out-of-Period Adjustment HTML 18K
17: R11 Convertible Debt HTML 21K
27: R12 Notes Payable - Related Party HTML 16K
38: R13 Stockholders' Equity HTML 18K
20: R14 Subsequent Events HTML 20K
18: R15 Significant Accounting Policies (Policies) HTML 58K
28: R16 Significant Accounting Policies (Tables) HTML 27K
39: R17 Business (Details Narrative) HTML 15K
22: R18 Going Concern and Management's Liquidity Plans HTML 27K
(Details Narrative)
16: R19 Significant Accounting Policies - Schedule of HTML 18K
Foreign Currency Translation Exchange Rate
(Details)
31: R20 Significant Accounting Policies - Schedule of HTML 25K
Potentially Dilutive Securities Excluded from
Computation of Net Loss Per Share (Details)
34: R21 Out-of-Period Adjustment (Details Narrative) HTML 38K
25: R22 Convertible Debt (Details Narrative) HTML 39K
13: R23 Notes Payable - Related Party (Details Narrative) HTML 19K
32: R24 Stockholders' Equity (Details Narrative) HTML 28K
35: R25 Subsequent Events (Details Narrative) HTML 48K
21: XML IDEA XML File -- Filing Summary XML 61K
33: EXCEL IDEA Workbook of Financial Reports XLSX 32K
6: EX-101.INS XBRL Instance -- accp-20190930 XML 379K
8: EX-101.CAL XBRL Calculations -- accp-20190930_cal XML 79K
9: EX-101.DEF XBRL Definitions -- accp-20190930_def XML 241K
10: EX-101.LAB XBRL Labels -- accp-20190930_lab XML 352K
11: EX-101.PRE XBRL Presentations -- accp-20190930_pre XML 319K
7: EX-101.SCH XBRL Schema -- accp-20190930 XSD 66K
12: ZIP XBRL Zipped Folder -- 0001493152-20-006905-xbrl Zip 47K
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Accelerated Pharma Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2019 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Michael Fonstein, CEO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ Michael Fonstein | |
| Michael Fonstein | |
| CEO | |
| Dated: April 22, 2020 |
A signed original of this written statement required by Section 906 has been provided to Accelerated Pharma, Inc. and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/22/20 | None on these Dates | ||
| For Period end: | 9/30/19 | |||
| List all Filings | ||||